help button home button The Oncologist
HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
First Published Online July 10, 2009
The Oncologist, Vol. 14, No. 7, 706-716, July 2009; doi:10.1634/theoncologist.2009-0013
© 2009 AlphaMed Press

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
theoncologist.2009-0013v1
14/7/706    most recent
Right arrow eLetters: Submit a response to this article
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article link to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Reprints/Permissions
Google Scholar
Right arrow Articles by Banerjee, S.
Right arrow Articles by Gore, M.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Banerjee, S.
Right arrow Articles by Gore, M.

Gynecologic Oncology

The Future of Targeted Therapies in Ovarian Cancer

Susana Banerjee, Martin Gore

The Royal Marsden Hospital, London, United Kingdom

Key Words. Ovarian cancer • Targeted therapy • VEGF inhibitors • PARP inhibitors

Correspondence: Martin Gore, Ph.D., F.R.C.P., The Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, United Kingdom. Telephone: 44-207-808-2198; Fax: 44-207-808-2475; e-mail: martin.gore{at}rmh.nhs.uk

Received January 22, 2009; accepted for publication June 12, 2009; first published online in THE ONCOLOGIST Express on July 10, 2009.

Disclosures: Susana Banerjee: None; Martin Gore: Consultant/advisory role: Roche, Pfizer, Bayer; Honoraria: Roche, Pfizer, Bayer.

The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships relevant to the content of this article have been disclosed by the independent peer reviewers.

Ovarian cancer is the second most common gynecological malignancy and the leading cause of death from gynecological cancer. Most women present with advanced disease with little prospect for cure. There have been some advances in surgical and chemotherapeutic strategies, but these approaches have led to only minor improvements in outcome. There remains a significant risk for recurrence and resistance to therapy, and hence there is a need to improve upon the current treatment options. Molecularly directed therapy aims to target tumor cells and the tumor microenvironment by blocking specific molecular changes in the cancer. The most promising agents so far are the antiangiogenic agents and polyadenosine diphosphate-ribose polymerase inhibitors. This article reviews the various targeted therapeutic approaches under clinical investigation in ovarian cancer and the challenges facing their future success in the clinic.






HOME HELP CONTACT US SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
THE ONCOLOGIST STEM CELLS CME ALPHAMED PRESS JOURNALS


Copyright © 2009 by AlphaMed Press.